Earnings season brings clarity—and volatility. This week, focus shifts to individual companies navigating sector-specific headwinds and tailwinds. AbbVie (ABBV) and Beyond Meat (BYND) offer contrasting narratives.
AbbVie's (ABBV) shares saw a modest increase, rising 0.44% to $233.11, following positive clinical trial results for its drug Skyrizi. Data revealed that 55% of Crohn's disease patients achieved clinical remission at week 12, significantly higher than the placebo group. Skyrizi also demonstrated a strong endoscopic response. These results bolster AbbVie's competitive position against Johnson & Johnson (JNJ) in the IBD market, where Skyrizi has already captured a substantial market share. While JNJ stock declined -0.43% to $247.35, the implications of AbbVie's Skyrizi data will be closely watched.
Conversely, Beyond Meat (BYND) experienced a significant setback, with shares falling 8.67% to $0.86. This decline partially reverses last week's rally, which was fueled by the announcement of new flavors for its Beyond Immerse sparkling protein drink line. Despite the company's efforts to innovate in the beverage sector with these drinks containing 10-20g of plant protein, 7g of fiber, and 60-100 calories, investors appear concerned about broader market trends and upcoming earnings. Wall Street anticipates a loss of $0.11 per share on $63 million in revenue for Beyond Meat's Q1 2023 earnings, scheduled for release on March 10.
Also of note, Sprout Social (SPRT) saw its price target lowered by Goldman Sachs to $8.00, and the stock fell -36.28% to $12.17. Compugen (CGEN) reported an EPS beat but a revenue miss. ADT also saw a divergence between earnings performance and revenue generation, highlighting how critical it is to analyze multiple metrics when assessing a company's financial health.
Expectations are set. Now comes execution.